Trial Profile

A Pilot, Randomized, Double-Blind, Active-Controlled, 2-Treatment, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Abuse Liability of Dextroamphetamine Sulfate From an Abuse-Deterrent Immediate-Release Formulation (ADAIR)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2021 According to a Vallon Pharma media release, positive data from this proof-of-concept intranasal human abuse study were presented at the 2020 American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting.
19 Jan 2021 According to a Vallon Pharma media release, result presented at the 2021 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting.
19 Jan 2021 Results presented in a Vallon Pharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com